Highly Concentrated Autologous Platelet-Rich Plasma Restores Foveal Anatomy in Lamellar Macular Hole Surgery

Abstract

Background Lamellar macular holes (LMHs) are an entity of a progressive disease in which the efficacy of the therapy of choice, vitrectomy, seems to be reduced. It is unknown whether highly concentrated autologous platelet-rich plasma (PRP) is of value in the therapy of LMHs. The purpose of this study was to gauge the potential of highly concentrated PRP to restore foveal anatomy in LMH surgery.

Patients and Methods In this interventional case series, eight eyes of eight patients with progressive LMH were included. All patients underwent a 23-gauge pars plana vitrectomy with induction of a posterior vitreous detachment and peeling of tractive epiretinal membranes whenever present. Under air tamponade, 0.1 mL of highly concentrated autologous PRP was applied. Subsequently, a gas or air tamponade was performed. All patients were instructed to rest in the supine position for the first 1 to 2 postoperative hours. Best-corrected visual acuity (BCVA) testing, microperimetry, spectral-domain optical coherence tomography (SD-OCT) and fundus photography were performed prior to and 3 months after surgery.

Results SD-OCT showed closure of the macular defect with restoration of a normal foveal configuration in all (8 of 8) patients 3 months postoperatively. BCVA improved significantly, from 0.28 ± 0.08 to 0.12 ± 0.14 logMAR (Wilcoxon: p = 0.03). Microperimetry remained unchanged (24.13 ± 1.96 vs. 23.7 ± 1.54 dB; p = 0.46). No clinically significant intra- or postoperative complications were observed.

Conclusion The use of highly concentrated PRP enables excellent anatomical and functional outcomes in the surgical therapy of LMH. Further prospective comparative trials are warranted to compare this promising technique with existing surgical strategies.

Zusammenfassung

Hintergrund Makulaschichtforamina sind eine progrediente Erkrankung, bei der die Wirksamkeit der Therapie der Wahl, der Vitrektomie, reduziert zu sein scheint. Das Potenzial von hochkonzentriertem autologem Thrombozytenkonzentrat (Platelet-rich Plasma, PRP) in der Therapie von Makulaschichtforamina ist unbekannt. Ziel dieser Studie ist die Beurteilung des Potenzials von hochkonzentriertem autologem Thrombozytenkonzentrat in der chirurgischen Therapie von Makulaschichtforamina.

Patienten und Methoden In diese interventionelle Fallserie wurden 8 Augen von 8 Patienten mit progressivem LMH eingeschlossen. Alle Patienten erhielten eine 23-Gauge-Pars-plana-Vitrektomie mit Induktion einer hinteren Glaskörperabhebung und Peeling traktiver epiretinaler Membranen, sofern vorhanden. Unter Lufttamponade wurde 0,1 ml hochkonzentriertes autologes Thrombozytenkonzentrat appliziert. Anschließend wurde eine Gas- oder Lufttamponade eingegeben. Alle Patienten wurden angewiesen, in den ersten 1 – 2 postoperativen Stunden in Rückenlage zu ruhen. Der bestkorrigierte Visus (BCVA), Mikroperimetrie, optische Kohärenztomografie (SD-OCT) und die Fundusfotografie erfolgten präoperativ sowie 3 Monate postoperativ.

Ergebnisse In der SD-OCT zeigte sich einen Verschluss des Makuladefekts mit Wiederherstellung der normalen fovealen Konfiguration bei allen (8 von 8) Patienten 3 Monate postoperativ. Die bestkorrigierte Sehschärfe verbesserte sich signifikant von 0,28 ± 0,08 auf 0,12 ± 0,14 logMAR (Wilcoxon: p = 0,03). Die Mikroperimetrie blieb stabil (24,13 ± 1,96 vs. 23,7 ± 1,54 dB; p = 0,46). Es wurden keine klinisch signifikanten intra- oder postoperativen Komplikationen beobachtet.

Schlussfolgerung Die Verwendung von hochkonzentriertem autologem Thrombozytenkonzentrat ermöglicht hervorragende anatomische und funktionelle Ergebnisse in der chirurgischen Therapie der Makulaschichtforamina. Weitere prospektive Vergleichsstudien sind notwendig, um diese vielversprechende Technik mit bestehenden chirurgischen Strategien zu vergleichen.

Key words

lamellar macular hole - platelet-rich plasma - vitrectomy - peeling - retina

Schlüsselwörter

Makulaschichtforamen - Thrombozytenkonzentrat - Vitrektomie - Peeling - Retina

Publication History

Received: 12 December 2020

Accepted: 18 February 2021

Article published online:
17 May 2021

• References

• 1 Gass JD. Lamellar macular hole: a complication of cystoid macular edema after cataract extraction. Arch Ophthalmol 1976; 94: 793-800 DOI: 10.1001/archopht.1976.03910030391008.
• 2 Bottoni F, Deiro AP, Giani A. et al. The natural history of lamellar macular holes: a spectral domain optical coherence tomography study. Graefes Arch Clin Exp Ophthalmol 2013; 251: 467-475 DOI: 10.1007/s00417-012-2044-2.
• 3 Hubschman JP, Govetto A, Spaide RF. et al. Optical coherence tomography-based consensus definition for lamellar macular hole. Br J Ophthalmol 2020; 104: 1741-1747 DOI: 10.1136/bjophthalmol-2019-315432.
• 4 Pang CE, Spaide RF, Freund KB. Epiretinal proliferation seen in association with lamellar macular holes: a distinct clinical entity. Retina 2014; 34: 1513-1523 DOI: 10.1097/iae.0000000000000163.
• 5 Compera D, Schumann RG, Cereda MG. et al. Progression of lamellar hole-associated epiretinal proliferation and retinal changes during long-term follow-up. Br J Ophthalmol 2018; 102: 84-90 DOI: 10.1136/bjophthalmol-2016-310128.
• 6 Marques MF, Rodrigues S, Raimundo M. et al. Epiretinal Proliferations Associated with Lamellar Macular Holes: Clinical and Surgical Implications. Ophthalmologica 2018; 240: 8-13 DOI: 10.1159/000486691.
• 7 Schumann RG, Hagenau F, Guenther SR. et al. Premacular Cell Proliferation Profiles in Tangential Traction Vitreo-Maculopathies Suggest a Key Role for Hyalocytes. Ophthalmologica 2019; 242: 106-112 DOI: 10.1159/000495853.
• 8 Figueroa MS, Noval S, Contreras I. Macular structure on optical coherence tomography after lamellar macular hole surgery and its correlation with visual outcome. Can J Ophthalmol 2011; 46: 491-497 DOI: 10.1016/j.jcjo.2011.09.011.
• 9 Gonzalez A, Amin S, Iqbal O. et al. Use of Autologous Platelets for Lamellar Macular Hole Repair. Case Rep Ophthalmol Med 2019; 2019: 1471754 DOI: 10.1155/2019/1471754.
• 10 Danielescu C, Stanca HT, Balta F. The Management of Lamellar Macular Holes: A Review. J Ophthalmol 2020; 2020: 3526316 DOI: 10.1155/2020/3526316.
• 11 Purtskhvanidze K, Balken L, Hamann T. et al. Long-term follow-up of lamellar macular holes and pseudoholes over at least 5 years. Graefes Arch Clin Exp Ophthalmol 2018; 256: 1067-1078 DOI: 10.1007/s00417-018-3972-2.
• 12 Schumann RG, Compera D, Schaumberger MM. et al. Epiretinal membrane characteristics correlate with photoreceptor layer defects in lamellar macular holes and macular pseudoholes. Retina 2015; 35: 727-735 DOI: 10.1097/iae.0000000000000375.
• 13 Takahashi K, Morizane Y, Kimura S. et al. Results of lamellar macular hole-associated epiretinal proliferation embedding technique for the treatment of degenerative lamellar macular hole. Graefes Arch Clin Exp Ophthalmol 2019; 257: 2147-2154 DOI: 10.1007/s00417-019-04425-9.
• 14 Liggett PE, Skolik DS, Horio B. et al. Human autologous serum for the treatment of full-thickness macular holes. A preliminary study. Ophthalmology 1995; 102: 1071-1076 DOI: 10.1016/s0161-6420(95)30909-8.
• 15 Gaudric A, Massin P, Paques M. et al. Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol 1995; 233: 549-554 DOI: 10.1007/bf00404704.
• 16 Rosenthal G, Bartz-Schmidt KU, Walter P. et al. Autologous platelet treatment for optic disc pit associated with persistent macular detachment. Graefes Arch Clin Exp Ophthalmol 1998; 236: 151-153 DOI: 10.1007/s004170050056.
• 17 Chow DR, Williams GA, Trese MT. et al. Successful closure of traumatic macular holes. Retina 1999; 19: 405-409 DOI: 10.1097/00006982-199909000-00006.
• 18 Purtskhvanidze K, Frühsorger B, Bartsch S. et al. Persistent Full-Thickness Idiopathic Macular Hole: Anatomical and Functional Outcome of Revitrectomy with Autologous Platelet Concentrate or Autologous Whole Blood. Ophthalmologica 2018; 239: 19-26 DOI: 10.1159/000481268.
• 19 Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83: 835-870 DOI: 10.1152/physrev.2003.83.3.835.
• 20 Andresen JL, Ledet T, Ehlers N. Keratocyte migration and peptide growth factors: the effect of PDGF, bFGF, EGF, IGF-I, aFGF and TGF-beta on human keratocyte migration in a collagen gel. Curr Eye Res 1997; 16: 605-613 DOI: 10.1076/ceyr.16.6.605.5081.
• 21 Burmeister SL, Hartwig D, Limb GA. et al. Effect of various platelet preparations on retinal muller cells. Invest Ophthalmol Vis Sci 2009; 50: 4881-4886 DOI: 10.1167/iovs.08-3057.